© Reuters. FILE PHOTO: FILE PHOTO: A vial and a syringe are seen in front of a displayed Pfizer logo in this illustration taken November 27, 2021. REUTERS/Dado Ruvic/Illustration/
(Reuters) – U.S. drugmaker Pfizer Inc (NYSE:) said on Monday it expects $10 billion to $15 billion in annual global revenue by 2030 from its portfolio of mRNA vaccines, which includes its COVID-19 vaccine as well as shots for flu and shingles.
Be the first to comment